Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 9, 2003, Pages 1279-1282

  Wood, Karen L ^a   Hage, Chadi A ^a   Knox, Kenneth S ^a   Kleiman, Martin B ^a   Sannuti, Aruna ^a   Day, Richard B ^a   Wheat, L Joseph ^a   Twigg III, Homer L ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OPW 425 ^*  (United States)

Author keywords

Anti tumor necrosis factor antibodies; Histoplasmosis; Interferon ; Tumor necrosis factor

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBODY; AZATHIOPRINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; ITRACONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; DRUG EFFECT; FEMALE; FUNGUS GROWTH; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON PRODUCTION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TH1 CELL;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DRUG MONITORING; FEMALE; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038216657     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200206-563OC     Document Type: Article

References (26)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. and Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602.
2. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, The Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody ca2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-1036.
3. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
4. Zhang Z, Correa H, Begue R. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-626.
5. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.
6. Hammerman KJ, Powell KE, Tosh FE. The incidence of hospitalized cases of systemic mycotic infections. Sabouraudia 1974;512:33-45.
7. Cano MV, Hajjeh RA. The epidemiology of histoplasmosis: a review. Semin Respir Infect 2001;16:109-118.
8. Kauffman CA, Israel KS, Smith JW, White AC, Schwarz J, Brooks GF. Histoplasmosis in immunosuppressed patients. Am J Med 1978;64:923-932.
9. Wheat LJ, Smith EJ, Sathapatayavongs B, Batteiger B, Filo RS, Leapman SB, French MV. Histoplasmosis in renal allograft recipients: two large urban outbreaks. Arch Intern Med 1983;143:703-707.
10. Newman SL. Cell-mediated immunity to Histoplasma capsulatum. Semin Respir Infect 2001;16:102-108.
11. Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-α exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998;160:6072-6082.
12. Zhou P, Miller G, Seder RA. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-α plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol 1998;160:1359-1368.
13. Allendorfer R, Brunner GD, Deepe GS Jr. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J Immunol 1999;162:7389-7396.
14. Twigg HL, Soliman DM, Day RB, Knox KS, Anderson RJ, Wilkes DS, Schnizlein-Bick CT. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;159:1439-1444.
15. Newman SL, Gootee L. Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun 1992;60:4593-4597.
16. Vail GM, Mocherla S, Wheat LJ, Goldberg J, Camp A, Brizendine E, Schnizlein-Bick C. Cellular immune response in HIV-infected patients with histoplasmosis. J Acquir Immune Defic Syndr 2002;29:49-53.
17. Fleischmann J, Wu-Hsieh B, Howard DH. The intracellular fate of Histoplasma capsulatum in human macrophages is unaffected by recombinant human interferon-gamma. J Infect Dis 1990;161:143-145.
18. Ma X. TNF-alpha and IL-12: a balancing act in macrophage functioning. Microbes Infect 2001;3:121-129.
19. Twigg HL III, Martin WJ II. Immunologic and nonimmunologic lung defense mechanisms. In: Middleton E Jr, editor. Allergy: principles and practice, 5th ed. St. Louis, MO: Mosby; 1998. p. 477-494.
20. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-2570.
21. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986;314:83-88.
22. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:100-107.
23. Peddi VR, Hariharan S, First MR. Disseminated histoplasmosis in renal allograft recipients. Clin Transplant 1996;10:160-165.
24. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002;4:148-151.
25. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, Goldman M, Thomas CJ, Gutsch HM, Moskovitz B, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:1049-1056.
26. McKinsey DS, Spiegel RA, Hutwagner L, Stanford J, Driks MR, Brewer J, Gupta MR, Smith DL, O'Connor MC, Dall L. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis 1997; 24:1195-1203.